Tardive dyskinesia and antipsychotics: A 5-year longitudinal study of frequency, correlates and course

International Clinical Psychopharmacology

Volumn 21, Issue 1, 2006, Pages 35-42

  Eberhard, Jonas ^a,c   Lindström, Eva ^b   Levander, Sten ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AIMS; Antipsychotics; Cognition; Involuntary movements; Psychosis; Risperidone; Schizophrenia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS; RISPERIDONE;

EID: 31744433349     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000182120.51672.7d     Document Type: Article

References (76)

1. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. (1999). Vitamine E treatment for tardive dyskinesia. Arch Gen Psychiatry 56:836-841.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Barany S, Haggstrom JE, Gunne LM (1983). Application of a primate model for tardive dyskinesia. Acta Pharmacol Toxicol (Copenh) 52:86-89.
4. Baribeau J, Laurent JP, Decary A (1993). Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurobiological approach. Brain Cogn 23:40-55.
5. Bowers MB, Swigar ME (1988). Psychotic patients who become worse on neuroleptics. J Clin Psychopharmacol 8:417-421.
6. Caroff SN, Mann SC (2002). Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63 (suppl 4):12-19.
7. Carvalho RC, Silva RH, Ablio VC, Barbosa PN, Frussa-Filho R (2003). Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice. Brain Res Bull 60:115-124.
8. Casey DE (1984). Tardive dyskinesia and affective disorders. In: Gardos G, Casey DE (editors): Tardive Dyskinesia and Affective Disorders. Washington, DC: American Psychiatric Press, pp. 2-19.
9. Casey DE (1987) Tardive dyskinesia. In: Meltzer HY (editor): Psychopharmacology. The Third Generation of Progress. New York: Raven Press, pp. 1411-1419.
10. Casey DE (1991). Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109-120.
11. Casey DE (1999). Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35 (suppl):61-66.
12. Chiu HKF, Lee S (1989). Tardive dyskinesia. Aust NZ J Psychiatr 23:566-570.
13. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:4141-4425.
14. DeWolfe AS, Ryan JJ, Wolf ME (1988). Cognitive sequele of tardive dyskinesis. J Nerv Ment Dis 176:270-274.
15. Eberhard J, Riley F, Levander S (2003). Premorbid IQ and schizophrenia - increasing cognitive reduction by episodes. Eur Arch Psy Clin Neurosci 253:84-88.
16. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2004). A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65:696-701.
17. Fenn DS, Moussaoui D, Hoffman WF, Kadri N, Bentounssi B, Tilane A, et al. (1996). Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology 123:206-210.
18. Gafoor R, Brophy J (2003). Three case reports of emergent dyskinesia with clozapine. Eur Psychiatry 18:260-261.
19. Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, et al. (1994). Ten-year outcome of tardive dyskinesia. Am J Psychiatry 151:836-841.
20. Gardos G, Cole JO (1995). The evaluation and treatment of neuroleptic-induced movement disorders. Harv Rev Psychiatry 3:130-139.
21. Gerlach J, Casey DE (1988). Tardive dyskinesia. Acta Psychiatr Scand 77:369-378.
22. Glazer WM (2000a). Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 61 (suppl 4):21-26.
23. Glazer WM (2000b). Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61 (suppl 3):16-21.
24. Glazer WM, Morgenstern H, Doucette JT (1993). Predicting the long-term risk of tardive dyskinesia in out-patients maintained on neuroleptic medications. J Clin Psychiatry 54:133-139.
25. Guy W (1976). ECDEU Assessment Manual for Psychopharmacolgy, rev edn. Washington, DC: US Department of Health, Education and Welfare, USGPO.
26. Ipekci S, Birsoz S (2001). Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine. Eur Psychiatry 16:259-260.
27. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, et al. (1995). Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52:756-765.
28. Jeste DV, Lacro JP (1999). Lower incidence of tardive dyskinesia with risperidone compared with haloperdol in older patients. J Am Geriatr Soc 47:716-719.
29. Kane J (1999). Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry 37:26-29.
30. Karson CN, Bracha HS, Powell A, Adams L (1990). Dyskinetic movements, cognitive impairment, and negative symptoms in elderly neuropsychiatric patients. Am J Psychiatry 147:1646-1649.
31. Karson CN, Lyon N, Amick R, Bracha HS, Guggenheim FG (1993). The profile of cognitive impairment in elderly dyskinetic subjects. J Neuropsychiatry Clin Neurosci 5:61-65.
32. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale for schizophrenia (PANSS). Schizophr Bull 13:261-276.
33. Kissling W (1989). Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Berlin: Springer-Verlag.
34. Klawans HL (1973). The psychopharmacology of tardive dyskinesia. Am J Psychiatry 130:82-86.
35. Kraepelin E (1919). Dementia Praecox and Paraphrenia. Edinburgh: E&S Livingstone.
36. Lieberman JA, Saltz BL, Johns CA, Pooacl S, Borenstein M, Kane J (1991). The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503-510.
37. Llorca PM, Chereau I, Bayle F-J, Lancon C (2002). Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17:129-138.
38. Lublin H, Eberhard J, Levander S (2005). Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20:183-198.
39. Lund BC, Perry PJ (2000). Olanzapine: an atypical antipsychotic for schizophrenia. Exp Opin Pharmacother 1:305-323.
40. Marsden CD, Jenner P (1980). The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55-72.
41. McCreadie RG, Latha S, Thara R, Padmavathi R, Ayankaran JR (1997). Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia. Br J Psychiatry 171:360-363.
42. Miller LG, Jankovic J (1989). Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 149: 2486-2492.
43. Moss LE, Neppe VM, Drevets WC (1993). Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 13:204-209.
44. Mouret J, Khomais M, Lemoine P, Sebert P (1991). Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture? Eur Neurol 31:199-203.
45. Myslobodsky MS, Tomer R, Holden T, Kempler S, Sigal M (1985). Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Dis 173: 156-160.
46. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N (2003). Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 64:1075-1080.
47. Perquin LNM (2005). Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 21: in press.
48. Pourcher E, Cohen H, Cohen D, Baruch P, Bouchard RH (1993). Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia. Brain Cogn 23:81-87.
49. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, et al. (2003). Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 160:1117-1124.
50. Rosenbaum AH, Niven RG, Hanson NP, Swanson DW (1977). Tardive dyskinesia: relationship with a primary affective disorder. Dis Nerv Syst 38:423-427.
51. Rush M, Diamond F, Alpert M (1982). Depression as a risk factor for tardive dyskinesia. Biol Psychiatry 17:387-392.
52. Sachdev PS (2000). The current status of tardive dyskinesia. Aust NZ J Psychiatry 34:355-369.
53. Sachdev P, Hume F, Toohey P, Doutney C (1996). Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia. Acta Psychiatrica Scand 93:451-459.
54. Schooler NR (1988). Evaluation of drug-related disorders in the aged. Psychopharmacol Bull 24:603-607.
55. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
56. Schwartz TL, Saba LM, Hardoby W, Virk S, Masand PS (2002). Use of atypical antipsyhotics in a Veteran Affairs Hospital. Prog Neuropsychopharmacol Biol Psychiatry 26:1207-1210.
57. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. (2001). Melatonin treatment for tardive dyskinesia. A double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 58:1049-1052.
58. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al. (1985). The pharmacological treatment of delusional depression. Am J Psychiatry 142:430-436.
59. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A (1997). Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 58:318-322.
60. Stanniland C, Taylor D (2000). Tolerability of atypical antipsyhotics. Drug Saf 22:195-214.
61. Struve FA, Willner AE (1983). Cognitive dysfunction and tardive dyskinesia. Br J Psychiatry 143:597-600.
62. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM (1994). Clozapine in tardive dyskinesia: observations from human and animal models. J Clin Psychiatry 55 (suppl B):102-106.
63. Tandon R (2002). Safety and tolerability: how do newer generation 'atypical' antipsychotics compare? Psychiatr Q 73:297-311.
64. Tegeler J, Strauss WH, Luthcke H, Bertling R (1988). Cognitive functions in schizophrenic patients with tardive dyskinesia. Pharmacopsychiatry 21:308-309.
65. von Knorring L, Lindström E (1992). The Swedish version of the positive and negative syndrome scale (PANSS) for schizophrenia. Construct validity and inter-rater reliability. Acta Psychiatr Scand 86:463-468.
66. Waddington JL (1995). Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Adv Neurol 65:211-229.
67. Waddington J, Youssef A (1996). Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 26: 681-688.
68. Waddington JL, Youssef HA, Dolphin C, Kinsella A (1987). Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 44:907-912.
69. Waddington JL, Youssef HA, Kinsella A (1990) Cognitive dysfunction in schizophrenia followed up for 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 20: 835-842.
70. Waddington JL, O'Callaghan E, Larkin C, Kinsella A (1993). Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain Cogn 23:56-70.
71. Wade JB, Taylor MA, Kasprisin A, Rosenberg S, Fiducia D (1987). Tardive dyskinesia and cognitive impairment. Biol Psychiatry 22:393-395.
72. Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Lieberman J (1985). Cognitive impairment in tardive dyskinesia. Psychiatry Res 16:331-337.
73. Wirshing WC (2001). Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 62 (suppl 21):15-18.
74. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, et al. (1991). The prevalence of tardive dyskinesia. J Clin Psychopharmacol 11:34-42.
75. Wolf ME, Ryan JJ, Mosnaim AD (1983). Cognitive function in tardive dyskinesia. Psychol Med 13:671-674.
76. Worrel JA, Marken PA, Beckman SE, Ruehter VL (2000). Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 57:238-255.